Teva to appeal EU’s $500m anti-competition fine

Nicholas PrattNovember 1, 2024
assortment of pharmaceutical medicine capsules, pills and tablets in bottle on blue background
Credit: Shutterstock/OlegDoroshin

Israeli drugmaker Teva Pharmaceuticals has launched an impassioned defence of its business practices after it was hit with a $503m (€462.6m) fine from the European Commission for anti-competitive behaviour.
Teva, which is con...

Want to read this article?

Register for ultimate access to this article and ALL our premium content

ULTIMATE ACCESS PROVIDES YOU WITH

  • Unrestricted access to Commercial Risk, Commercial Risk Europe and Global Risk Manager news, exclusive expert analysis and opinion
  • Breaking news, daily and/or weekly Commercial Risk Europe newsletters and regular digital publications
  • Breaking news, weekly and monthly Global Risk Manager newsletters and quarterly digital Journal
  • European and global surveys, rankings and special reports
  • National European local language newsletters
  • Preferential access to webinars and virtual and physical conferences

If you are already a registered user or subscriber you can LOGIN below for ultimate access:

Nicholas PrattNovember 1, 2024
Back to top button